Abstract
A monoclonal antibody, McAb9E (IgG3), was generated against a metastatic HCC cell line, MHCC-1. The antigen was characterized as human Caveolin-1 (Cav-1, 21kDa), with pI of 5.65. The Cav-1 antigen was found significantly over expressed in metastatic HCC cell lines as well as in tumor specimens. The Cav-1 specific McAb may be a useful molecular agent for metastatic HCC.
Keywords: Hepatocellular carcinoma, caveolin-1, monoclonal antibody, metastasis
Protein & Peptide Letters
Title: Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential
Volume: 16 Issue: 5
Author(s): Mei-yu Hu, Chi-tat Lam, Kang-da Liu, Zhi Xu, Sarwat Fatima, Yvonne C.F Su, Felice Tsang, Jie Chen, Jin-zhong Pang, Lun-xiu Qin and J. M. Luk
Affiliation:
Keywords: Hepatocellular carcinoma, caveolin-1, monoclonal antibody, metastasis
Abstract: A monoclonal antibody, McAb9E (IgG3), was generated against a metastatic HCC cell line, MHCC-1. The antigen was characterized as human Caveolin-1 (Cav-1, 21kDa), with pI of 5.65. The Cav-1 antigen was found significantly over expressed in metastatic HCC cell lines as well as in tumor specimens. The Cav-1 specific McAb may be a useful molecular agent for metastatic HCC.
Export Options
About this article
Cite this article as:
Hu Mei-yu, Lam Chi-tat, Liu Kang-da, Xu Zhi, Fatima Sarwat, Su C.F Yvonne, Tsang Felice, Chen Jie, Pang Jin-zhong, Qin Lun-xiu and Luk M. J., Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential, Protein & Peptide Letters 2009; 16 (5) . https://dx.doi.org/10.2174/092986609788167743
DOI https://dx.doi.org/10.2174/092986609788167743 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implications of Kidney Disease on Metabolic Reduction
Current Drug Metabolism A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomarkers Editorial
Current Radiopharmaceuticals The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science New Perspectives in Glioblastoma: Nanoparticles-based Approaches
Current Cancer Drug Targets MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
Current Drug Targets An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy